Original Study| Volume 15, ISSUE 6, e1081-e1088, December 2017

Everolimus Versus Axitinib as Second-line Therapy in Metastatic Renal Cell Carcinoma: Experience From Institut Gustave Roussy

Published:August 11, 2017DOI:



      Everolimus (E) and axitinib (A) have been standard treatments for patients with metastatic renal cell carcinoma after failure of first-line therapy (1L) with vascular endothelial growth factor-targeted therapy. This study aims to compare both drugs in a large comprehensive cancer center.


      Patient characteristics and outcome data from all patients with metastatic renal cell carcinoma who received E or A as second-line therapy at Gustave Roussy from April 2007 to May 2015 have been recorded.


      A total of 81 patients were treated with E and 45 patients with A. There were no major differences between the 2 groups. The most common 1L was sunitinib (79% in the E group and 82.2% in the A group). The median follow-up was 29 months; 26 months for A and 33 months for E (P = .046). The median overall survival (OS) was 21.5 months for E and 14.9 months for A (P = .23). The median progression-free survival (PFS) was 5.3 and 7.7 months for E and A, respectively (P = .39). Partial response was achieved in 4% and in 24% of patients (P = .002) in the E and A cohort, respectively. In the A group, the median PFS and OS were statistically different according to response, tumor burden, and 1L duration. No differences were found in the E arm.


      In this series, there are no significant differences for PFS and OS with E and A. A appears to provide more objective response. A appears to be more effective in patients with small tumor burden, responders to 1L, and 1L therapy > 12 months.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Clinical Genitourinary Cancer
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Ferlay J.
        • Soerjomataram I.
        • Dikshit R.
        • et al.
        Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012.
        Int J Cancer. 2015; 136: E359-E386
        • Fisher R.
        • Gore M.
        • Larkin J.
        Current and future systemic treatments for renal cell carcinoma.
        Semin Cancer Biol. 2013; 23: 38-45
      1. Howlader N, Noone AM, Krapcho M, et al. SEER Cancer Statistic Fact Sheets. 2014. Available at:

        • Motzer R.J.
        • Hutson T.E.
        • Tomczak P.
        • et al.
        Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma.
        J Clin Oncol. 2009; 27: 3584-3590
        • Escudier B.
        • Pluzanska A.
        • Koralewski P.
        • et al.
        Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial.
        Lancet. 2007; 370: 2103-2111
        • Escudier B.
        • Eisen T.
        • Stadler W.M.
        • et al.
        Sorafenib in advanced clear-cell renal-cell carcinoma.
        N Engl J Med. 2007; 356: 125-134
        • Sternberg C.N.
        • Hawkins R.E.
        • Wagstaff J.
        • et al.
        A randomised, double-blind phase III study of pazopanib in patients with advanced and/or metastatic renal cell carcinoma: final overall survival results and safety update.
        Eur J Cancer. 2013; 49: 1287-1296
        • Motzer R.J.
        • Hutson T.E.
        • Cella D.
        • et al.
        Pazopanib versus sunitinib in metastatic renal-cell carcinoma.
        N Engl J Med. 2013; 369: 722-731
        • Levy A.
        • Menard J.
        • Albiges L.
        • et al.
        Second line treatment of metastatic renal cell carcinoma: the Institut Gustave Roussy experience with targeted therapies in 251 consecutive patients.
        Eur J Cancer. 2013; 49: 1898-1904
        • Alimohamed N.
        • Lee J.L.
        • Srinivas S.
        • et al.
        A population-based overview of sequences of targeted therapy in metastatic renal cell carcinoma.
        Clin Genitourin Cancer. 2014; 12: e127-e131
        • Motzer R.J.
        • Escudier B.
        • Oudard S.
        • et al.
        Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial.
        Lancet. 2008; 372: 449-456
        • Rini B.I.
        • Escudier B.
        • Tomczak P.
        • et al.
        Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial.
        Lancet. 2011; 378: 1931-1939
        • Heng D.Y.
        • Signorovitch J.
        • Swallow E.
        • et al.
        Comparative effectiveness of second-line targeted therapies for metastatic renal cell carcinoma: a systematic review and meta-analysis of real-world observational studies.
        PLoS One. 2014; 9: e114264
        • Sherman S.
        • Amzal B.
        • Calvo E.
        • et al.
        An indirect comparison of everolimus versus axitinib in US patients with advanced renal cell carcinoma in whom prior sunitinib therapy failed.
        Clin Ther. 2015; 11: 2552-2559
        • Vogelzang N.J.
        • Pal S.K.
        • Signorovitch J.E.
        • et al.
        Comparative effectiveness of everolimus and axitinib as second targeted therapies for metastatic renal cell carcinoma in the US: a retrospective chart review.
        Curr Med Res Opin. 2016; 32: 741-747
        • Motzer R.J.
        • Escudier B.
        • McDermott D.F.
        • et al.
        Nivolumab versus everolimus in advanced renal-cell carcinoma.
        N Engl J Med. 2015; 373: 1803-1813
        • Choueiri T.K.
        • Escudier B.
        • Powles T.
        • et al.
        Cabozantinib versus everolimus in advanced renal-cell carcinoma.
        N Engl J Med. 2015; 373: 1814-1823
        • Grunwald V.
        • McKay R.R.
        • Krajewski K.M.
        • et al.
        Depth of remission is a prognostic factor for survival in patients with metastatic renal cell carcinoma.
        Eur Urol. 2015; 67: 952-958